ArticleDiabetes2020
Repeated Pharmacogenetic Catecholamine Neuron Activation in the Ventrolateral Medulla Attenuates Subsequent Glucoregulatory Responses.
Article in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Repeated chemogenetic activation of C1 catecholamine neurons reduces subsequent glucoprivic responses and mimics HAAF.Endocrinology · 2026Article
- Glycemic Challenge Is Associated with the Rapid Cellular Activation of the Locus Ceruleus and Nucleus of Solitary Tract: Circumscribed Spatial Analysis of Phosphorylated MAP Kinase Immunoreactivity.Journal of clinical medicine · 2023Article
- Current and future therapies to treat impaired awareness of hypoglycemia.Frontiers in pharmacology · 2023Review
- Brain-Body Control of Glucose Homeostasis-Insights From Model Organisms.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hindbrain catecholamine (CA) neurons are essential for elicitation of protective counterregulatory responses (CRRs) to glucose deficit, including increased feeding and elevation of circulating corticosterone, epinephrine, and glucose. Severe or repeated antecedent glucoprivation results in attenuation of these CRRs and failure to correct glucose deficit, constituting a potentially lethal condition known as hypoglycemia-associated autonomic failure (HAAF) that may occur in patients with diabetes on insulin therapy. Recently, we demonstrated that selective pharmacogenetic activation of CA neuron subpopulations in the ventrolateral medulla during normoglycemia elicits these CRRs in a site-specific manner. In the present experiment, we examined the effect of repeated pharmacogenetic activation of CA neurons in the A1/C1 cell group on subsequent elicitation of feeding, corticosterone secretion, and respiratory quotient. We found that this prior treatment attenuated these responses to subsequent pharmacogenetic stimulation, similar to attenuation of these CRRs following repeated antecedent glucoprivation. This suggests that functional impairment of A1/C1 CA neurons resulting from antecedent glucoprivation may account, at least in part, for impairment of specific CRRs critical for restoration of normoglycemia in response to glucose deficit. Thus, a pharmacogenetic approach to selective activation of key neural circuits could provide a means of identifying neuropathogenic mechanisms contributing to HAAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.